Abbott acquires Aventis’ Mavik
Abbott Labs acquires full manufacturing and commercial rights to Aventis' cardiovascular drugs Mavik and Tarka for $300 mil. plus royalties. Abbott already holds marketing rights to Mavik (trandolapril) and Tarka (trandolapril/verapamil) in the U.S. and other countries under a 1991 licensing deal. Aventis will retain rights to the products in Japan. Combined global sales topped $200 mil. in 2003; Abbott believes sales of the two drugs could eventually reach $700 mil. The divestiture is not related to the Sanofi merger, Aventis says...
You may also be interested in...
The Belgian start-up is developing a scleral contact lens with an inbuilt LCD screen capable of filtering light – offering a non-surgical solution to a variety of ophthalmic conditions.
EU Regulatory Roundup, November 2023: Notified Body Advances But Sector Still Demands System Rethink
There is currently a melting pot of ideas concerning the future of the EU’s medtech regulatory system due to its shortfalls. All the while progress is being made, especially in the area notified bodies.
Stada has struck a deal with CR Sanjiu for distribution and promotion of its cough and cold brands after identifying expansion in the Chinese market as a key strategic target.